HomeCompareFPHAF vs GBDC

FPHAF vs GBDC: Dividend Comparison 2026

FPHAF yields 60.61% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.18M in total portfolio value· pulled ahead in Year 7
10 years
FPHAF
FPHAF
● Live price
60.61%
Share price
$3.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$671.2K
Annual income
$158,074.64
Full FPHAF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — FPHAF vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFPHAFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FPHAF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FPHAF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FPHAF
Annual income on $10K today (after 15% tax)
$5,151.52/yr
After 10yr DRIP, annual income (after tax)
$134,363.44/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,848,760.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FPHAF + GBDC for your $10,000?

FPHAF: 50%GBDC: 50%
100% GBDC50/50100% FPHAF
Portfolio after 10yr
$10.76M
Annual income
$8,304,404.24/yr
Blended yield
77.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

FPHAF
No analyst data
Altman Z
-17.1
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FPHAF buys
0
GBDC buys
0
No recent congressional trades found for FPHAF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFPHAFGBDC
Forward yield60.61%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$671.2K$20.85M
Annual income after 10y$158,074.64$16,450,733.83
Total dividends collected$557.6K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: FPHAF vs GBDC ($10,000, DRIP)

YearFPHAF PortfolioFPHAF Income/yrGBDC PortfolioGBDC Income/yrGap
1$16,761$6,060.61$12,492$1,791.70+$4.3KFPHAF
2$27,427$9,493.40$16,527$3,160.58+$10.9KFPHAF
3$43,866$14,518.80$23,588$5,904.90+$20.3KFPHAF
4$68,638$21,701.63$37,141$11,901.65+$31.5KFPHAF
5$105,179$31,735.61$66,205$26,463.38+$39.0KFPHAF
6$157,990$45,448.98$137,452$66,612.65+$20.5KFPHAF
7← crossover$232,853$63,803.27$342,372$195,298.53$109.5KGBDC
8$337,036$87,884.16$1,053,292$686,954.33$716.3KGBDC
9$479,513$118,883.79$4,111,439$2,984,416.95$3.63MGBDC
10$671,153$158,074.64$20,849,974$16,450,733.83$20.18MGBDC

FPHAF vs GBDC: Complete Analysis 2026

FPHAFStock

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

Full FPHAF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this FPHAF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FPHAF vs SCHDFPHAF vs JEPIFPHAF vs OFPHAF vs KOFPHAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.